+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
P

Actively Recruiting

Researchers are evaluating calderasib alone and in combination with other therapies for people with advanced solid tumors that have a specific KRAS G12C mutation. The study is designed to assess the safety, how the body processes the drug pharmacokinetics, and the effectiveness of calderasib and its combinations. Participants have advanced cancers confirmed by specific tests and have often received prior treatments. Participants are assigned to one of several groups receiving different treatments. Some receive daily oral doses of calderasib alone with doses increasing up to 800 mg, adjusted as needed for safety. Others receive calderasib combined with pembrolizumab infusions every 21 days for up to 35 cycles 24 months, sometimes with additional chemotherapy drugs like carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, or 5-fluorouracil according to standard dosing schedules. Treatments continue until the disease progresses or participants stop. During the study, participants have regular visits for drug dosing and safety monitoring. Researchers track side effects, dose-limiting toxicities, and treatment discontinuations over months. Blood samples are taken at specific times to measure drug levels and how the body absorbs and clears calderasib. The main outcomes include safety measures up to about 56 months and response rates. This long study period helps understand how participants respond and tolerate the treatments over time.

Age: 18Years +All GendersPhase 1
75 locations
P

Actively Recruiting

Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.

Age: 18Years +All GendersPhase 3
185 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a new medicine called vepugratinib in adults with advanced or metastatic urothelial carcinoma, a type of bladder cancer with a specific FGFR3 genetic alteration. This phase 3 trial compares vepugratinib with a placebo when both are given alongside enfortumab vedotin and pembrolizumab. The study aims to understand if adding vepugratinib improves treatment outcomes and monitors adverse events over an extended period. Participants will receive oral vepugratinib or a matching placebo combined with intravenous enfortumab vedotin and pembrolizumab. The treatments are given in parallel groups, with some participants receiving the experimental drug and others the placebo, all alongside the standard IV therapies. The trial includes a safety lead-in phase and an extended treatment period, with study participation lasting up to approximately six years. During the trial, participants will undergo regular assessments including monitoring of treatment-related side effects, imaging to evaluate tumor response, blood tests to measure drug levels, and quality of life questionnaires. Researchers will track progression-free survival, overall survival, and response rates throughout the study and follow participants closely for safety and health status until study completion.

Age: 18Years +All GendersPhase 3
276 locations

1-10 of 23

1